Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07682662 · ClinicalTrials.gov registry record · Phase 4
Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis
A Phase 4 study, sponsored by University of Mississippi Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 400
- Enrollment target
NCT07682662 is a Phase 4 study that has not yet begun recruiting, run by University of Mississippi Medical Center. The registered enrollment target is 400 participants.
The verdict
NCT07682662, a Phase 4 study, has not yet begun recruiting, sponsored by University of Mississippi Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 400 participants
- Enrollment target
Study Summary
The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are: Does Ketamine lower the number of times participants need to be admitted for continued pain control during a Sickle Cell Pain Crisis. Does Ketamine decrease the amount of time it takes to reach adequate pain control/pain score improvement, as compared to Opioids. Patients could have too low or too high blood pressure or sleepiness. Researchers will compare Ketamine to Opioids (Morphine or Dilaudid) to see if Ketamine works to treat pain enough that you do not need to be admitted to the hospital. Participants will: On arrival to the Children's ER for Sickle Cell Pain crisis will get Ketamine, instead of Morphine or Dilaudid, along with the typical Tylenol, Toradol, Lidocaine patch for pain control while in the ER. During this time we will follow your reported pain scale (0-10) to monitor your pain response to the Ketamine, as well as follow rate of hospital admission.
Interventions
- OTHER Standard Care (in control arm)
- DRUG Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2029-10-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07682662
The ClinicalTrials.gov registry entry for NCT07682662 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Mississippi Medical Center, which has 96 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard Care (in control arm) is the first listed.
NCT07682662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07682662 about?
NCT07682662 is a clinical study titled "Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis". The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are: Does Ketamine lower the number of times participants need to be admitted for continued pain control during a Sickle Cell Pain Crisis. Does K...
What is the current status of trial NCT07682662?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 400 participants. The study started on 2026-08-01. Estimated completion is 2029-10-01.
What interventions are being tested in trial NCT07682662?
The interventions under investigation include: Standard Care (in control arm) (OTHER), Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses. (DRUG).
Who is sponsoring clinical trial NCT07682662?
This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.